相关临床试验
0
0 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Tyra Biosciences reported initial Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer, identifying 60 mg once daily as the dose for its planned adjuvant strategy. - In single marker lesion patients (n=8), dabogratinib 60 mg QD achieved 100% overall response rate and a 75% best overall complete response rate, while combined single and multiple lesion patients (n=14) showed 79% ORR and 64% CR. - Safety was favorable with no Grade 4 or 5 events, no clinically significant hyperphosphatemia, nail or ocular toxicity, and no dose reductions or treatment-related discontinuations at 60 mg. - Despite the efficacy signal, Tyra shares fell roughly 20-22% as the 64% complete response rate missed the 70% benchmark analysts had set, and the company now plans a 70 mg cohort for the ablative setting.
- UroGen Pharma Chief Medical Officer Mark Schoenberg sold 10,000 ordinary shares for $400,000 on July 9, 2026, under a pre-established Rule 10b5-1 trading plan. - The sale occurred with UroGen's market capitalization at $2.0 billion and shares priced at $40.23, following a 191.31% one-year stock appreciation. - Schoenberg retains 119,763 ordinary shares directly following the transaction, which represents the concluding trade of the August 2025 trading plan schedule. - The company reported trailing 12-month revenue of $140.5 million and a net loss of $133.2 million, with Zusduri and Jelmyto driving commercial performance.
- UroGen Pharma has reached a settlement agreement with Teva Pharmaceuticals that resolves patent litigation over JELMYTO, granting Teva a non-exclusive license to sell its generic version beginning September 15, 2030. - The agreement preserves nearly all of UroGen's patent protection period for JELMYTO, which has regulatory exclusivity through April 2027 and Orange Book-listed patents expiring January 20, 2031. - JELMYTO is approved for treating low-grade upper tract urothelial cancer using UroGen's proprietary RTGel reverse-thermal hydrogel technology that enables sustained drug release. - The settlement reinforces the value of UroGen's innovation and intellectual property portfolio while allowing continued execution of their mission to transform uro-oncology treatment paradigms.
- UroGen Pharma reported robust Phase 3 clinical data for pipeline candidate UGN-103 and secured FDA agreement for a clear regulatory pathway toward New Drug Application submission. - The company's newly launched bladder cancer treatment ZUSDURI achieved record-breaking early demand with widespread insurance coverage across major payers. - CMS approved a permanent J-code for ZUSDURI effective January 2026, addressing previous commercial adoption bottlenecks and supporting revenue growth projections. - UroGen's financial narrative projects $463.3 million in revenue by 2028, requiring 70% annual revenue growth despite current net losses of $155 million.
- The FDA approved UroGen Pharma's Zusduri as the first drug to treat non-muscle invasive bladder cancer that hasn't spread beyond the inner layers of the organ. - In a late-stage trial with 223 patients, 78% showed complete response with all signs of cancer disappearing after treatment. - The gel-based formulation offers a non-surgical alternative to traditional procedures, administered as a simple drug instillation in a doctor's office. - The approval addresses a significant unmet need for approximately 82,000 Americans affected by this type of bladder cancer annually, with 59,000 experiencing recurrence.
- UroGen Pharma's stock plummeted approximately 47% after an FDA advisory committee voted against its bladder cancer therapy UGN-102 (mitomycin), citing concerns over study design. - The FDA had repeatedly recommended a randomized trial design, noting that the Envision trial's lack of a concurrent control arm made primary endpoints difficult to interpret. - Despite UroGen reporting an 80.6% probability of patients remaining in complete response at 18 months, the regulatory setback highlights challenges in developing alternatives to surgical intervention for bladder cancer.
- UroGen Pharma has submitted a new drug application for UGN-102 ahead of schedule, with FDA review underway and a target decision date of June 13, 2025. - The Envision Phase 3 trial demonstrated exceptional efficacy with UGN-102 achieving a 79.6% complete response rate at 3 months and 82.3% duration of response at 12 months in bladder cancer patients. - Despite reporting a $126.9 million net loss for 2024, UroGen maintains a strong balance sheet with $241.7 million in cash and is expanding its sales force from 52 to 83 representatives in preparation for commercial launch.
• UroGen Pharma's UGN-102 New Drug Application has been accepted by the FDA, with a decision expected by June 13, 2025. • The ENVISION Phase 3 trial data highlights a 79.6% complete response rate at three months and an 82.3% durability of response at 12 months. • UGN-102, a mitomycin-based intravesical solution, could become the first FDA-approved treatment for low-grade intermediate-risk non-muscle invasive bladder cancer. • The UTOPIA Phase 3 trial for UGN-103, targeting recurrent LG-IR-NMIBC, has commenced, expanding UroGen's pipeline.
• A Phase I dose-escalation study is evaluating UGN-301 (zalifrelimab) as monotherapy and in combination with UGN-201 or gemcitabine for recurrent non-muscle invasive bladder cancer (NMIBC). • The study aims to determine the biologically effective dose and recommended Phase II dose of UGN-301, assessing safety, tolerability, and preliminary efficacy. • Key endpoints include the incidence of treatment-emergent adverse events, dose-limiting toxicities, and complete response rate in patients with carcinoma in situ (CIS). • Recruitment is ongoing for this multi-part trial, which includes patients with high-grade or intermediate-risk NMIBC who have failed prior BCG therapy.
• UroGen Pharma's UGN-102 shows an 82.3% duration of response at 12 months in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC). • The Phase 3 ENVISION trial highlights a 79.6% complete response rate at 3 months following the initial UGN-102 instillation, indicating a promising treatment for LG-IR-NMIBC. • UGN-102's safety profile remains consistent with previous trials, reinforcing its potential as a valuable option for patients facing repeated surgical interventions. • The FDA has set a PDUFA goal date of June 13, 2025, for UGN-102, potentially marking it as the first FDA-approved treatment for LG-IR-NMIBC.
